-
2023
-
FDA Denies Petition to Grant Simufilam Breakthrough Designation
-
Ractigen’s ALS Drug Candidate Gains Orphan Drug Designation
-
AstraZeneca says cancer drug Enhertu showed positive results
-
FDA will review Eisai and Biogen’s Alzheimer’s treatment Leqembi with decision on full approval expected in early July
-
Future of generative AI in pharma
-
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
-
ForCast Orthopedics Gets QIDP Nod for Investigational Antibiotic
-
Gene Therapy Consortium to Launch Rare Diseases Pilot
-
FDA’s approval of Friedreich’s ataxia drug is a game changer for treatment of rare diseases
-
FDA Accepts IND and Grants Priority Review for SpringWorks Desmoid Tumors Therapeutic